Delisting risk
Moleculin Biotech (MBRX)
Developing Annamycin with cytarabine for relapsed or refractory acute myeloid leukemia.
$0.6916
Pre-market−0.01 (−0.82%)
At close$0.6973(+7.28%)
Something off on this page? Send us feedback.
Next report
Nov 12, 2026
in 70 days
EPS estimate
−$0.44
Revenue estimate
—
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.37−$17.25−$12.25−$3.25$2.61−$3.54−$1.40Pending
Estimate−$1.54−$17.75−$9.75−$5.00−$7.77−$1.69−$1.55−$0.44
Surprise+76.0%+2.8%−25.6%+35.0%+133.6%−109.5%+9.7%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported———————Pending
Estimate————————
Surprise————————
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.44 | — | — |
| Aug 2026 | −$1.55 | −$1.40 | +9.7% |
| May 2026 | −$1.69 | −$3.54 | −109.5% |
| Mar 2026 | −$7.77 | $2.61 | +133.6% |
| Nov 2025 | −$5.00 | −$3.25 | +35.0% |
The latest year is open to everyone — the 39 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Apr 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| Jun 2016 | |||
| Sep 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | −$0.44 | — | — | — | — | — | — |
| Aug 13, 2026 | −$1.55 | −$1.40 | +9.7% | — | — | — | +9.4% |
| May 14, 2026 | −$1.69 | −$3.54 | −109.5% | — | — | — | −4.1% |
| Mar 20, 2026 | −$7.77 | $2.61 | +133.6% | — | — | — | +1.9% |
| Nov 13, 2025 | −$5.00 | −$3.25 | +35.0% | — | — | — | −4.4% |
The latest year is open to everyone — the 39 quarters behind it read with an account. Sign in | |||||||
| Aug 12, 2025 | |||||||
| May 13, 2025 | |||||||
| Mar 21, 2025 | |||||||
| Nov 11, 2024 | |||||||
| Aug 13, 2024 | |||||||
| May 10, 2024 | |||||||
| Mar 22, 2024 | |||||||
| Nov 13, 2023 | |||||||
| Aug 11, 2023 | |||||||
| May 11, 2023 | |||||||
| Mar 22, 2023 | |||||||
| Nov 10, 2022 | |||||||
| Aug 15, 2022 | |||||||
| May 11, 2022 | |||||||
| Mar 25, 2022 | |||||||
| Nov 11, 2021 | |||||||
| Aug 12, 2021 | |||||||
| May 12, 2021 | |||||||
| Mar 24, 2021 | |||||||
| Nov 13, 2020 | |||||||
| Aug 12, 2020 | |||||||
| May 11, 2020 | |||||||
| Mar 19, 2020 | |||||||
| Nov 12, 2019 | |||||||
| Aug 16, 2019 | |||||||
| May 13, 2019 | |||||||
| Feb 21, 2019 | |||||||
| Nov 13, 2018 | |||||||
| Aug 13, 2018 | |||||||
| May 15, 2018 | |||||||
| Mar 28, 2018 | |||||||
| Nov 14, 2017 | |||||||
| Aug 14, 2017 | |||||||
| May 15, 2017 | |||||||
| Apr 3, 2017 | |||||||
| Nov 21, 2016 | |||||||
| Aug 15, 2016 | |||||||
| Jun 16, 2016 | |||||||
| Sep 30, 2015 | |||||||